Charles River Laboratories International (CRL) Aktie Kurs
Charles River Laboratories International Kurs
Under de senaste 19 åren växte Charles River Laboratories International intäkterna med 7,3 % årligen och nådde 4,02 Mrd USD. Vinst per aktie har minskat med 13,1 % per år under de senaste 17 åren. För Charles River Laboratories International är nettovinstmarginal på −3,6 % ned jämfört med 11,0 % för några år sedan. Det konsensusbaserade 12-månaderskursmålet för Charles River Laboratories International är 273,00 USD, cirka under kursen med 9,1 %. Av 23 analytiker ger 17 köpråd — den samlade bedömningen är Köp.
Charles River Laboratories International aktiekurs
Charles River Laboratories International affärsmodell och aktieanalys
Vanliga frågor om Charles River Laboratories International-aktien
The business model of Charles River Laboratories International Inc primarily revolves around providing research and development (R&D) solutions and services to the pharmaceutical, biotechnology, and medical device companies. As a leading contract research organization (CRO), the company offers a wide range of preclinical and clinical laboratory services, including safety assessment, discovery support, manufacturing support, and laboratory animal research services. Charles River Laboratories operates on a fee-for-service basis, collaborating with its clients to accelerate drug discovery, development, and commercialization processes. With a focus on quality, reliability, and scientific expertise, the company aims to support its clients in advancing their scientific research and achieving their business goals.
Charles River Laboratories International Inc is primarily active in the life sciences industry.
Some of the main competitors of Charles River Laboratories International Inc in the market include Covance Inc., Envigo, PPD, Eurofins Scientific, and LabCorp.
Charles River Laboratories International Inc is a renowned company in the field of preclinical and clinical laboratory services. Founded in 1947, Charles River has built a strong reputation as a trusted provider of comprehensive research support. With a focus on helping pharmaceutical and biotechnology companies bring new drugs to market, they offer a wide range of services including drug discovery, safety assessment, and manufacturing support to clients worldwide. The company's expertise in advanced animal models, laboratory sciences, and support services has propelled it to the forefront of the life sciences industry. Today, Charles River Laboratories continues to play a vital role in advancing much-needed medical therapies.
Charles River Laboratories International Inc has achieved several significant milestones. It has consistently demonstrated strong financial performance, delivering consistent revenue growth and expanding its global footprint. The company has successfully completed strategic acquisitions, enabling it to enhance its capabilities and expand its service offerings. Charles River Laboratories International Inc has also received notable recognition, including being named one of the World's Most Ethical Companies for several consecutive years. Moreover, the company has been at the forefront of scientific advancements, collaborating with global pharmaceutical and biotechnology companies to develop innovative solutions that improve drug discovery and development processes.
Charles River Laboratories International Inc is primarily present in the following countries and regions: United States, Canada, Europe, Asia Pacific, and Latin America.
Charles River Laboratories International Inc represents various values and corporate philosophies. The company is committed to their mission of improving the lives of people and animals through innovative research and development. They aim to maintain the highest standards of scientific integrity, ethical conduct, and regulatory compliance. Charles River Laboratories prioritizes collaboration and partnership with their clients to provide comprehensive solutions and exceptional service. With a focus on quality, efficiency, and expertise, they strive to consistently deliver reliable and innovative scientific services and products. Through their dedication to responsible and sustainable practices, Charles River Laboratories aims to make a positive impact on society and the environment.
Analytiker sätter för närvarande ett genomsnittligt riktkurs på 267,60 USD för Charles River Laboratories International-aktien (median: 273,00 USD), vilket innebär −10,9 % mot senaste kurs. Konsensus baseras på 23 analytikerbetyg.
Charles River Laboratories International Analytikers kursmål 2026
23 analytiker betygsätter för närvarande Charles River Laboratories International-aktien: 17 rekommenderar köp, 6 behåll och 0 sälj. För 2026 väntar sig analytiker att Charles River Laboratories International genererar intäkter på 3,91 Mrd USD och vinst per aktie på 11,44 USD.
Charles River Laboratories International Analytikers kursmål 2026
Omräknat till aktuell växelkurs handlas Charles River Laboratories International-aktien till 268,46 EUR (300,49 USD).
Charles River Laboratories International-aktien (CRL) är noterad på 6 börser, bland annat: NYSE (CRL), SIX (Zürich) (RV6.SW), XETRA (RV6.DE), Frankfurt (RV6.F), München (RV6.MU), Düsseldorf (RV6.DU).
Charles River Laboratories International Inc is a global leader in the field of life sciences, offering its customers a wide range of products and services. The company's business model is based on three main areas: research and development, preclinical services, and bioproducts. Research and Development: Charles River Laboratories offers a variety of services to support its customers in the development of new products. These include chemical and pharmacological screening systems, study design and planning, cell and tissue banking, genotoxicology, protein and antibody production, and much more. Charles River Laboratories has a comprehensive range of scientific and technical capabilities to assist its customers in the development of new drugs, biotechnology products, and medical devices. Preclinical Services: The company provides its customers with a wide range of preclinical services to test the safety and efficacy of products. These services include toxicology, pathology, pharmacology, bioanalytics, and clinical diagnostics. Charles River Laboratories has several preclinical research facilities worldwide and can support customers in the validation of new therapies and products. Bioproducts: Charles River Laboratories produces a variety of bioproducts for research and development, including cell lines, antibodies, nucleic acids, and proteins. The company also offers specialized services such as genetic manipulation and custom modification of cell lines to achieve specific research goals. The company focuses on customer loyalty and has earned the trust of customers by offering high-quality products and services. Charles River Laboratories has a global presence with facilities in North America, Europe, and Asia, and can serve customers worldwide. The company also maintains a strong partnership with the scientific community by supporting research initiatives and public health measures. Charles River Laboratories is committed to offering its customers a comprehensive range of services to meet their needs in the field of life sciences. The company is dedicated to continuously improving its research and development and introducing new services and products to meet the ever-changing needs of customers.
Omsättningen för förväntad Charles River Laboratories International är 3,91 Mrd USD. Denna siffra baseras på aktuella finansiella data och återspeglar företagets affärsresultat.
Nettovinsterna för förväntad Charles River Laboratories International är 563,17 M USD. Nettovinsterna återspeglar företagets lönsamhet efter avdrag för alla utgifter.
Kurs-vinstkvoten (P/E) för Charles River Laboratories International är för närvarande 26,26. P/E-talet jämför den aktuella aktiekursen med vinsten per aktie och hjälper investerare att bedöma värderingen av Charles River Laboratories International-aktien.
Kurs-försäljningskvoten (P/S) för Charles River Laboratories International är för närvarande 3,78. P/S-talet jämför börsvärdet med den årliga omsättningen och fungerar som ett värderingsmått för Charles River Laboratories International-aktien.
Eulerpool Quality Score för Charles River Laboratories International är 3/10.
ISIN för Charles River Laboratories International är US1598641074. ISIN (International Securities Identification Number) är en globalt unik identifierare för värdepapper.
WKN för Charles River Laboratories International är 939391. WKN (Wertpapierkennnummer) är ett sexsiffrigt tyskt identifieringsnummer för värdepapper.
Tickern för Charles River Laboratories International är CRL. Tickersymbolen används för att handla Charles River Laboratories International-aktier på börsen.
Charles River Laboratories International aktie
Charles River Laboratories International Jämförbar grupp
Charles River Laboratories International Ticker
Charles River Laboratories International FIGI
Alla nyckeltal och djupgående analys av Charles River Laboratories International
Vår aktieanalys av Charles River Laboratories International-aktien innehåller viktiga finansiella nyckeltal som omsättning, vinst, P/E-tal, P/S-tal, EBIT samt information om utdelningen. Dessutom granskar vi aspekter såsom aktier, börsvärde, skulder, eget kapital och skuldförbindelser hos Charles River Laboratories International. Om du söker mer detaljerad information om dessa ämnen erbjuder vi på våra undersidor ingående analyser: